Stock LPCN LIPOCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
4.44 USD -7.50% Intraday chart for Lipocine Inc. -6.72% +59.14%
Apr. 12 Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial MT
Apr. 11 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial
MT
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
AQ
Top Premarket Gainers
MT
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
CI
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
PR
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
CI
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug
MT
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
PR
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
CI
Lipocine : Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - Form 8-K
PU
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
AQ
Lipocine : Announces Financial Results for the Full Year Ended December 31, 2023 - Form 8-K
PU
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lipocine to Present at 36th Annual Roth Conference
PR
Lipocine : to Present at 36th Annual Roth Conference - Form 8-K
PU
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
PR
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
CI
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
PR
Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada
AQ
Lipocine Enters Licensing Deal With Verity Pharmaceuticals for TLANDO in US, Canada
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPCN Stock
  4. News Lipocine Inc.